NCT02303626 Phase 2, phase 3 Completed
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Study sponsor: BioCryst Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2016-01 Actual
Enrollment · participants 110 Actual
Source updated 2025-11-17 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-11-17 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: The mean acute angioedema attack rate
+ After Measure: The Mean Acute Angioedema Attack Rate
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial